Trump's Pharma Deals May Undercut Drug Cost Controls, Analysts Warn
Source Summary
Analysts say private pharmaceutical deals negotiated under Trump's administration involve drugmakers agreeing to lower prices in Medicaid while maintaining higher prices in Medicare. These arrangements may undermine broader efforts to control drug costs across federal programs.
Why it matters
These deals may limit the government's ability to negotiate lower drug prices across Medicare, the largest federal healthcare program, potentially affecting millions of beneficiaries.
